JP2008504289A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008504289A5 JP2008504289A5 JP2007518346A JP2007518346A JP2008504289A5 JP 2008504289 A5 JP2008504289 A5 JP 2008504289A5 JP 2007518346 A JP2007518346 A JP 2007518346A JP 2007518346 A JP2007518346 A JP 2007518346A JP 2008504289 A5 JP2008504289 A5 JP 2008504289A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- substitution
- amino acid
- alanine
- substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US58318404P | 2004-06-25 | 2004-06-25 | |
| US62415304P | 2004-11-02 | 2004-11-02 | |
| PCT/US2005/022738 WO2006004663A2 (en) | 2004-06-25 | 2005-06-24 | Increasing the production of recombinant antibodies in mammalian cells by site-directed mutagenesis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008504289A JP2008504289A (ja) | 2008-02-14 |
| JP2008504289A5 true JP2008504289A5 (enExample) | 2008-07-31 |
Family
ID=35783288
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007518346A Withdrawn JP2008504289A (ja) | 2004-06-25 | 2005-06-24 | 部位特異的突然変異誘発による哺乳動物細胞における組換え抗体の産生の増加 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US20060019342A1 (enExample) |
| EP (1) | EP1773391A4 (enExample) |
| JP (1) | JP2008504289A (enExample) |
| AU (1) | AU2005259992A1 (enExample) |
| CA (1) | CA2572133A1 (enExample) |
| WO (1) | WO2006004663A2 (enExample) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2584130A1 (en) * | 2004-10-18 | 2006-04-27 | Medimmune, Inc. | High cell density process for growth of listeria |
| CA2602035C (en) | 2005-03-18 | 2015-06-16 | Medimmune, Inc. | Framework-shuffling of antibodies |
| AU2006232287B2 (en) * | 2005-03-31 | 2011-10-06 | Chugai Seiyaku Kabushiki Kaisha | Methods for producing polypeptides by regulating polypeptide association |
| CN104761637B (zh) | 2006-03-31 | 2021-10-15 | 中外制药株式会社 | 调控抗体血液动力学的方法 |
| EP2009101B1 (en) | 2006-03-31 | 2017-10-25 | Chugai Seiyaku Kabushiki Kaisha | Antibody modification method for purifying bispecific antibody |
| ES2429407T3 (es) | 2006-06-08 | 2013-11-14 | Chugai Seiyaku Kabushiki Kaisha | Agente preventivo o remedio para enfermedades inflamatorias |
| TWI422594B (zh) * | 2007-02-02 | 2014-01-11 | Baylor Res Inst | 經由樹狀細胞去唾液酸糖蛋白受體（ｄｃ-ａｓｇｐｒ）接合抗原呈現細胞之藥劑 |
| EP2132226B1 (en) * | 2007-02-23 | 2019-03-27 | Baylor Research Institute | Activation of human antigen-presenting cells through dendritic cell lectin-like oxidized ldl receptor-1 (lox-1) |
| WO2009023760A1 (en) * | 2007-08-14 | 2009-02-19 | Smithkline Beechan Corporation | Novel methods and cell lines |
| KR101680906B1 (ko) | 2007-09-26 | 2016-11-30 | 추가이 세이야쿠 가부시키가이샤 | 항체 정상영역 개변체 |
| ES2595638T3 (es) * | 2007-09-26 | 2017-01-02 | Chugai Seiyaku Kabushiki Kaisha | Método para modificar el punto isoeléctrico de un anticuerpo mediante la sustitución de aminoácidos en una CDR |
| TW201634479A (zh) | 2007-12-05 | 2016-10-01 | 中外製藥股份有限公司 | 抗ｎｒ１０抗體及其應用 |
| CA2708065C (en) | 2007-12-05 | 2015-02-24 | Chugai Seiyaku Kabushiki Kaisha | Therapeutic agent for pruritus |
| KR102057826B1 (ko) | 2008-04-11 | 2019-12-20 | 추가이 세이야쿠 가부시키가이샤 | 복수 분자의 항원에 반복 결합하는 항원 결합 분자 |
| TWI599577B (zh) * | 2008-09-26 | 2017-09-21 | Chugai Pharmaceutical Co Ltd | Methods to alter the isoelectric point of antibodies using amino acid substitutions of CDR regions |
| TWI440469B (zh) * | 2008-09-26 | 2014-06-11 | Chugai Pharmaceutical Co Ltd | Improved antibody molecules |
| EP2826789A1 (en) | 2009-03-19 | 2015-01-21 | Chugai Seiyaku Kabushiki Kaisha | Antibody constant region variant |
| JP5717624B2 (ja) | 2009-03-19 | 2015-05-13 | 中外製薬株式会社 | 抗体定常領域改変体 |
| RU2536941C2 (ru) | 2009-06-10 | 2014-12-27 | Стефен Саниг Ресерч Инститьют Лтд. | Способы получения клеток, проявляющих фенотипическую пластичность |
| US10150808B2 (en) | 2009-09-24 | 2018-12-11 | Chugai Seiyaku Kabushiki Kaisha | Modified antibody constant regions |
| ES2784123T3 (es) * | 2009-11-04 | 2020-09-22 | Merck Sharp & Dohme | Anticuerpo anti TSLP genomodificado |
| WO2011108714A1 (ja) | 2010-03-04 | 2011-09-09 | 中外製薬株式会社 | 抗体定常領域改変体 |
| TWI452136B (zh) | 2010-11-17 | 2014-09-11 | 中外製藥股份有限公司 | A multiple specific antigen-binding molecule that replaces the function of Factor VIII in blood coagulation |
| EP2647706B1 (en) | 2010-11-30 | 2023-05-17 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly |
| MX352889B (es) | 2011-02-25 | 2017-12-13 | Chugai Pharmaceutical Co Ltd | Anticuerpo de fc especifico para fcyriib. |
| JP6322411B2 (ja) | 2011-09-30 | 2018-05-09 | 中外製薬株式会社 | 複数の生理活性を有する抗原の消失を促進する抗原結合分子 |
| TW201817744A (zh) | 2011-09-30 | 2018-05-16 | 日商中外製藥股份有限公司 | 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子 |
| WO2014030750A1 (ja) | 2012-08-24 | 2014-02-27 | 中外製薬株式会社 | マウスFcγRII特異的Fc抗体 |
| SG10201709559PA (en) | 2012-08-24 | 2017-12-28 | Chugai Pharmaceutical Co Ltd | Fcγriib-specific fc region variant |
| CN105246914B (zh) | 2013-04-02 | 2021-08-27 | 中外制药株式会社 | Fc区变体 |
| ES2881306T3 (es) | 2013-09-27 | 2021-11-29 | Chugai Pharmaceutical Co Ltd | Método para la producción de heteromultímeros de polipéptidos |
| WO2015175957A1 (en) | 2014-05-16 | 2015-11-19 | Baylor Research Institute | Methods and compositions for treating autoimmune and inflammatory conditions |
| MA40764A (fr) | 2014-09-26 | 2017-08-01 | Chugai Pharmaceutical Co Ltd | Agent thérapeutique induisant une cytotoxicité |
| BR112017011235A2 (pt) | 2014-12-19 | 2018-02-06 | Chugai Pharmaceutical Co Ltd | anticorpos anti-c5 e métodos de uso |
| KR101860280B1 (ko) | 2014-12-19 | 2018-05-21 | 추가이 세이야쿠 가부시키가이샤 | 항-마이오스타틴 항체, 변이체 Fc 영역을 함유하는 폴리펩타이드, 및 사용 방법 |
| KR102605798B1 (ko) | 2015-02-05 | 2023-11-23 | 추가이 세이야쿠 가부시키가이샤 | 이온 농도 의존적 항원 결합 도메인을 포함하는 항체, Fc 영역 개변체, IL-8에 결합하는 항체, 및 그들의 사용 |
| CA2972393A1 (en) | 2015-02-27 | 2016-09-01 | Chugai Seiyaku Kabushiki Kaisha | Composition for treating il-6-related diseases |
| JP7082484B2 (ja) | 2015-04-01 | 2022-06-08 | 中外製薬株式会社 | ポリペプチド異種多量体の製造方法 |
| JP5954916B1 (ja) | 2015-04-14 | 2016-07-20 | 中外製薬株式会社 | Ｉｌ−３１アンタゴニストを有効成分として含有する、アトピー性皮膚炎の予防用及び／又は治療用医薬組成物 |
| WO2017110981A1 (en) | 2015-12-25 | 2017-06-29 | Chugai Seiyaku Kabushiki Kaisha | Anti-myostatin antibodies and methods of use |
| AU2016381992B2 (en) | 2015-12-28 | 2024-01-04 | Chugai Seiyaku Kabushiki Kaisha | Method for promoting efficiency of purification of Fc region-containing polypeptide |
| US11072666B2 (en) | 2016-03-14 | 2021-07-27 | Chugai Seiyaku Kabushiki Kaisha | Cell injury inducing therapeutic drug for use in cancer therapy |
| CR20180554A (es) | 2016-04-28 | 2019-01-10 | Chugai Pharmaceutical Co Ltd | Preparaciones que contienen anticuerpos |
| EP3494991A4 (en) | 2016-08-05 | 2020-07-29 | Chugai Seiyaku Kabushiki Kaisha | COMPOSITION FOR THE PROPHYLAXIS OR TREATMENT OF IL-8 RELATED DISEASES |
| SG10201607778XA (en) | 2016-09-16 | 2018-04-27 | Chugai Pharmaceutical Co Ltd | Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use |
| CN110461358A (zh) | 2017-03-31 | 2019-11-15 | 公立大学法人奈良县立医科大学 | 可用于预防和/或治疗凝血因子ⅸ异常、包含代替凝血因子ⅷ的功能的多特异性抗原结合分子的药物组合物 |
| WO2018203545A1 (ja) | 2017-05-02 | 2018-11-08 | 国立研究開発法人国立精神・神経医療研究センター | Ｉｌ－６及び好中球の関連する疾患の治療効果の予測及び判定方法 |
| CN119161488A (zh) | 2017-11-01 | 2024-12-20 | 中外制药株式会社 | 具有降低的生物活性的抗体变体和同种型 |
| CN112119090B (zh) | 2018-03-15 | 2023-01-13 | 中外制药株式会社 | 对寨卡病毒具有交叉反应性的抗登革热病毒抗体及使用方法 |
| GB201820006D0 (en) * | 2018-12-07 | 2019-01-23 | Lifearc | Humanised anti-IL17BR antibody |
| MX2022005654A (es) | 2019-11-20 | 2022-06-22 | Chugai Pharmaceutical Co Ltd | Preparacion que contiene anticuerpo. |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4444887A (en) * | 1979-12-10 | 1984-04-24 | Sloan-Kettering Institute | Process for making human antibody producing B-lymphocytes |
| GB8928874D0 (en) * | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| EP1400536A1 (en) * | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| US6800738B1 (en) * | 1991-06-14 | 2004-10-05 | Genentech, Inc. | Method for making humanized antibodies |
| ES2176484T3 (es) * | 1995-08-18 | 2002-12-01 | Morphosys Ag | Bancos de proteinas/(poli)peptidos. |
| US6262238B1 (en) * | 1997-01-14 | 2001-07-17 | Roche Diagnostic, Gmbh | Process for modifying the stability of antibodies |
| US6455677B1 (en) * | 1998-04-30 | 2002-09-24 | Boehringer Ingelheim International Gmbh | FAPα-specific antibody with improved producibility |
| PE20021080A1 (es) * | 2001-04-12 | 2003-02-12 | Boehringer Ingelheim Int | Un anticuerpo especifico fapo bibh1 en el tratamiento del cancer |
| ATE525398T1 (de) * | 2002-05-10 | 2011-10-15 | Medimmune Inc | Epha2 monoklonale antikörper und deren anwendungsverfahren |
| TWI335821B (en) * | 2002-12-16 | 2011-01-11 | Genentech Inc | Immunoglobulin variants and uses thereof |
| JP2007525458A (ja) * | 2003-04-23 | 2007-09-06 | メダレックス インコーポレイテッド | インターフェロンα受容体−１（ＩＦＮＡＲ−１）に対するヒト化抗体 |
| WO2005035575A2 (en) * | 2003-08-22 | 2005-04-21 | Medimmune, Inc. | Humanization of antibodies |
-
2005
- 2005-06-24 CA CA002572133A patent/CA2572133A1/en not_active Abandoned
- 2005-06-24 WO PCT/US2005/022738 patent/WO2006004663A2/en not_active Ceased
- 2005-06-24 US US11/165,023 patent/US20060019342A1/en not_active Abandoned
- 2005-06-24 EP EP05788064A patent/EP1773391A4/en not_active Withdrawn
- 2005-06-24 AU AU2005259992A patent/AU2005259992A1/en not_active Abandoned
- 2005-06-24 JP JP2007518346A patent/JP2008504289A/ja not_active Withdrawn
-
2010
- 2010-02-16 US US12/706,264 patent/US20100145028A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008504289A5 (enExample) | ||
| Shi et al. | Latent TGF-β structure and activation | |
| Nemčovičová et al. | Structure of human cytomegalovirus UL141 binding to TRAIL-R2 reveals novel, non-canonical death receptor interactions | |
| FI3715372T3 (fi) | Suuren affiniteetin humaaneja vasta-aineita ihmisen IL-4-reseptorille | |
| JP7382383B2 (ja) | 産生細胞株エンハンサー | |
| Wang et al. | The HMGB1 acidic tail regulates HMGB1 DNA binding specificity by a unique mechanism | |
| JP2014527802A5 (enExample) | ||
| JP2005120106A5 (enExample) | ||
| Wu et al. | LMP1 protein from the Epstein-Barr virus is a structural CD40 decoy in B lymphocytes for binding to TRAF3 | |
| ES2738641T3 (es) | Producción de proteínas terapéuticas en células de mamífero modificadas genéticamente | |
| JP2017509335A5 (enExample) | ||
| JP2020500510A5 (enExample) | ||
| Ryseck et al. | Characterization of elements determining the dimerization properties of RelB and p50 | |
| Salier | Chromosomal location, exon/intron organization and evolution of lipocalin genes | |
| Herbert | The ancient Z-DNA and Z-RNA specific Zα fold has evolved modern roles in immunity and transcription through the natural selection of flipons | |
| Riechmann et al. | Early protein evolution: building domains from ligand-binding polypeptide segments | |
| Hennicke et al. | Transient pentameric IgM fulfill biological function—Effect of expression host and transfection on IgM properties | |
| KR20130088845A (ko) | 인간 사이토메갈로 바이러스 감염의 검출 방법 | |
| Aguayo-Ortiz et al. | Thermodynamic stability of human γD-crystallin mutants using alchemical free-energy calculations | |
| McKown et al. | Conserved regional 3′ grouping of rare codons in the coding sequence of ocular prosecretory mitogen lacritin | |
| Chen et al. | Optimization on Fc for improvement of stability and aggregation resistance | |
| Jiang et al. | Characterization of substrate binding of the WW domains in human WWP2 protein | |
| O’Shea et al. | Reliable repurposing of the antibody interactome inside the cell | |
| JP6753143B2 (ja) | ＦｃγＲＩＩａをコードするポリヌクレオチド及びＦｃγＲＩＩａの製造方法 | |
| Madhumalar et al. | Dimerization of the core domain of the p53 family: a computational study |